BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 35587601)

  • 1. T Cells Engineered to Express Immunoreceptors Targeting the Frequently Expressed Medullary Thyroid Cancer Antigens Calcitonin, CEA, and RET M918T.
    Erickson TA; Shih YP; Fass J; Jang M; Tran E
    Thyroid; 2022 Jul; 32(7):789-798. PubMed ID: 35587601
    [No Abstract]   [Full Text] [Related]  

  • 2. Multiple Endocrine Neoplasia Type 2B Associated Mixed Medullary and Follicular Thyroid Carcinoma in A Chinese Patient with RET M918T Germline Mutation.
    Qi XP; Lin GB; Chen B; Li F; Cao ZL; Zheng WH; Zhao JQ
    Endocr Metab Immune Disord Drug Targets; 2021; 21(3):554-560. PubMed ID: 32660411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma.
    Cote GJ; Evers C; Hu MI; Grubbs EG; Williams MD; Hai T; Duose DY; Houston MR; Bui JH; Mehrotra M; Waguespack SG; Busaidy NL; Cabanillas ME; Habra MA; Luthra R; Sherman SI
    J Clin Endocrinol Metab; 2017 Sep; 102(9):3591-3599. PubMed ID: 28911154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of CDKN2C Copy Number in Sporadic Medullary Thyroid Carcinoma.
    Grubbs EG; Williams MD; Scheet P; Vattathil S; Perrier ND; Lee JE; Gagel RF; Hai T; Feng L; Cabanillas ME; Cote GJ
    Thyroid; 2016 Nov; 26(11):1553-1562. PubMed ID: 27610696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multilayer OMIC Data in Medullary Thyroid Carcinoma Identifies the STAT3 Pathway as a Potential Therapeutic Target in
    Mancikova V; Montero-Conde C; Perales-Paton J; Fernandez A; Santacana M; Jodkowska K; Inglada-Pérez L; Castelblanco E; Borrego S; Encinas M; Matias-Guiu X; Fraga M; Robledo M
    Clin Cancer Res; 2017 Mar; 23(5):1334-1345. PubMed ID: 27620278
    [No Abstract]   [Full Text] [Related]  

  • 6. [Medullary thyroid carcinoma].
    Tiedje V; Ting S; Dralle H; Schmid KW; Führer D
    Internist (Berl); 2015 Sep; 56(9):1019-31. PubMed ID: 26338063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective RET kinase inhibition for patients with RET-altered cancers.
    Subbiah V; Velcheti V; Tuch BB; Ebata K; Busaidy NL; Cabanillas ME; Wirth LJ; Stock S; Smith S; Lauriault V; Corsi-Travali S; Henry D; Burkard M; Hamor R; Bouhana K; Winski S; Wallace RD; Hartley D; Rhodes S; Reddy M; Brandhuber BJ; Andrews S; Rothenberg SM; Drilon A
    Ann Oncol; 2018 Aug; 29(8):1869-1876. PubMed ID: 29912274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
    Kurzrock R; Atkins J; Wheler J; Fu S; Naing A; Busaidy N; Hong D; Sherman S
    Ann Oncol; 2013 Sep; 24(9):2256-61. PubMed ID: 23676418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RET Proto-oncogene Gene Mutation Is Related to Cervical Lymph Node Metastasis in Medullary Thyroid Carcinoma.
    Wang S; Wang B; Xie C; Ye D
    Endocr Pathol; 2019 Dec; 30(4):297-304. PubMed ID: 31494787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Search of the p.M918T Mutation in the RET Oncogene in Mexican Adult Patients with Medullary Thyroid Carcinoma.
    Ruiz-Garcia E; Vidal-Millan S; Lopez-Yañez A; Torres JAP; Guadarrama-Orozco JA; Lino-Silva LS; Meneses-Garcia A; Astudillo-de la Vega H; Garcia MG
    Exp Clin Endocrinol Diabetes; 2017 Apr; 125(4):218-222. PubMed ID: 28166591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medullary thyroid carcinoma cell lines contain a self-renewing CD133+ population that is dependent on ret proto-oncogene activity.
    Zhu W; Hai T; Ye L; Cote GJ
    J Clin Endocrinol Metab; 2010 Jan; 95(1):439-44. PubMed ID: 19897677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.
    Bentzien F; Zuzow M; Heald N; Gibson A; Shi Y; Goon L; Yu P; Engst S; Zhang W; Huang D; Zhao L; Vysotskaia V; Chu F; Bautista R; Cancilla B; Lamb P; Joly AH; Yakes FM
    Thyroid; 2013 Dec; 23(12):1569-77. PubMed ID: 23705946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Precision medicine in endocrinology exemplified by medullary thyroid cancer].
    Brandenburg T; Machlah YM; Führer D
    Inn Med (Heidelb); 2024 Mar; 65(3):202-210. PubMed ID: 38231404
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Qi XP; Jin BY; Li PF; Wang S; Zhao YH; Cao ZL; Yu XH; Cheng J; Fang XD; Zhao JQ
    Thyroid; 2019 Oct; 29(10):1447-1456. PubMed ID: 31364476
    [No Abstract]   [Full Text] [Related]  

  • 15. Tumor Grade and Molecular Characteristics Associated with Survival in Sporadic Medullary Thyroid Carcinoma.
    Censi S; Galuppini F; Clausi C; Battheu F; Manso J; Piva I; Corvaglia S; Pedron MC; Mondin A; Iacobone M; Torresan F; Merante Boschin I; Bertazza L; Barollo S; Pennelli G; Mian C
    Thyroid; 2024 Feb; 34(2):177-185. PubMed ID: 38047536
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical and pathological analysis of 19 cases of medullary thyroid carcinoma without an increase in calcitonin.
    Zhou Q; Yue S; Cheng Y; Jin J; Xu H
    Exp Toxicol Pathol; 2017 Oct; 69(8):575-579. PubMed ID: 28552629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis and pathologic characteristics of medullary thyroid carcinoma-review of current guidelines.
    Thomas CM; Asa SL; Ezzat S; Sawka AM; Goldstein D
    Curr Oncol; 2019 Oct; 26(5):338-344. PubMed ID: 31708652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utilizing the circulating tumor markers in diagnosis and management of medullary thyroid cancer.
    Zarkesh M; Arab N; Tavangar SM; Nozhat Z; Fanaei SM; Hedayati M
    Pathol Res Pract; 2022 Jan; 229():153694. PubMed ID: 34929598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of RET mutations on the expression of tyrosine kinases in medullary thyroid carcinoma.
    Rodríguez-Antona C; Muñoz-Repeto I; Inglada-Pérez L; de Cubas AA; Mancikova V; Cañamero M; Maliszewska A; Gómez A; Letón R; Leandro-García LJ; Comino-Méndez I; Sanchez L; Alvarez-Escolá C; Aller J; Cascón A; Robledo M
    Endocr Relat Cancer; 2013 Aug; 20(4):611-9. PubMed ID: 23780998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple endocrine neoplasia type 2B mutation in human RET oncogene induces medullary thyroid carcinoma in transgenic mice.
    Acton DS; Velthuyzen D; Lips CJ; Höppener JW
    Oncogene; 2000 Jun; 19(27):3121-5. PubMed ID: 10871866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.